Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients.

Ann Nucl Med

Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.

Published: July 2022

Objective: This study aimed to assess the potential of Ga-DOTA-FAPI-04 PET/CT for the detection of the radioiodine-refractory differentiated thyroid cancer (RR-DTC) lesions.

Methods: We analyzed the Ga-DOTA-FAPI-04 PET/CT imaging data of 24 RR-DTC patients (7 men and 17 women; 49.6 ± 10.5 year). Clinical data were collected including history, last post-therapeutic radioiodine whole body scan, contemporary CT, thyroglobulin, and antithyroglobulin. Target lesions were selected and measured by the RECIST 1.1. The mean growth rates of the target lesions in the past 6 months were recorded. Tumor uptake of lesions were quantified by SUVmax and the tumor-to-background ratios. The correlation between SUVmax and target lesion growth rate and thyroglobulin was analyzed.

Results: On patient-based analysis, positive metastases were detected in 87.5% (21/24) patients. Except for the lymph node (LN) metastasis of 3 patients (patient 6, 12 and 17#) and the lung metastasis of another 3 patients (patient 9, 13 and 21#), most of the lesions were positive on Ga-DOTA-FAPI-04 PET/CT images, including LN metastasis and distant metastasis such as lung, bone and pleura. There were altogether 33 target lesions including 30 lung metastases and 3 LN metastases with the mean SUVmax and the growth rate were 4.25 and 6.51%, respectively. SUVmax was statistically associated with the growth rates of the target lesions (p = 0.047). No statistically significant correlation was found between the SUVmax and the serum thyroglobulin levels (p = 0.139).

Conclusions: Ga-DOTA-FAPI-04 PET/CT has a promising detection rate for RR-DTC metastasis. The FAPI uptake of the tumor may provide a potential therapeutic target for RR-DTC.

Trial Registry: NIH Clinical Trials.gov (NCT04499365).

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-022-01742-8DOI Listing

Publication Analysis

Top Keywords

ga-dota-fapi-04 pet/ct
20
target lesions
16
pet/ct imaging
8
radioiodine-refractory differentiated
8
differentiated thyroid
8
thyroid cancer
8
cancer rr-dtc
8
rr-dtc patients
8
growth rates
8
rates target
8

Similar Publications

Purpose: The study aimed to compare the diagnostic accuracy of Ga-DOTA-FAPI-04 (Ga-FAPI) and F-FDG PET/CT for peritoneal carcinomatosis (PC) in patients with various types of cancer.

Methods: The study enrolled 113 patients with suspected peritoneal malignancy, each of whom underwent Ga-FAPI and F-FDG PET/CT scans. Lesions in all patients were confirmed through pathology or radiological follow-up.

View Article and Find Full Text PDF

Preoperative assessment of pancreatic cancer with [Ga]Ga-DOTA-FAPI-04 PET/MR versus [F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study.

Eur J Nucl Med Mol Imaging

February 2025

Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China.

Purpose: To assess the diagnostic performance of [Ga]Ga-DOTA-FAPI-04 PET/MR imaging in the preoperative evaluation of pancreatic cancer and compare it with that of [F]-FDG PET/CT plus contrast-enhanced CT (CECT).

Methods: Thirty-one patients with pancreatic cancer underwent preoperative [Ga]Ga-DOTA-FAPI-04 PET/MR, [F]-FDG PET/CT, and CECT imaging. Two nuclear medicine physicians independently reviewed two sets of images (set 1, [Ga]Ga-DOTA-FAPI-04 PET/MR; set 2, [F]-FDG PET/CT plus CECT) and reached a consensus on tumour resectability, N staging (N0 or N positive) and M staging (M0 or M1).

View Article and Find Full Text PDF

In medullary thyroid carcinoma (MTC), distant metastases have few therapeutic options with low success rates and substantial toxicity in many patients, warranting exploration of alternate systemic treatments with fewer adverse effects. The fibroblast activation protein inhibitor (FAPI)-based PET/CT opens new avenues for several cancers, including MTC. A case of MTC with varying tracer avidity and interlesional heterogeneity on 18 F-FDG, 68 Ga-DOTATATE, and 68 Ga-DOTA-FAPI-04 PET/CT imaging is presented.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the feasibility and effectiveness of a one-stop dual-tracer PET/CT imaging method using [F]FDG and [Ga]Ga-FAPI-04 for cancer evaluation at a short interval post-injection.
  • The results showed that the one-stop imaging method provided higher tumor-to-normal ratios (TNRs) compared to the traditional two-day protocol, with better lesion detectability and reduced radiation exposure.
  • Overall, one-stop FDG-FAPI PET/CT could offer sufficient diagnostic information for clinical use and is a promising alternative to longer imaging protocols.
View Article and Find Full Text PDF
Article Synopsis
  • - A case study is presented involving a man diagnosed with malignant melanoma, who showed a thickened right breast during a PET/CT scan using 68Ga-DOTA-FAPI-04.
  • - The scan indicated increased tracer uptake, suggesting a possible issue with the breast tissue.
  • - However, follow-up ultrasound tests revealed that the thickening was benign gynecomastia and did not indicate any signs of malignancy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!